Clinical Trial Update: Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of tislelizumab monotherapy and tislelizumab-based combinations in resectable non-small cell lung cancer. The update reports on efficacy, safety, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-02-09